Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery
International Journal of Nanomedicine2015Vol. 10, pp. 5489–5489
Citations Over TimeTop 10% of 2015 papers
Young‐Il Jeong, Hyung Kyu Park, Sang-Joon Lee, Jong‐Suk Oh, Sam‐Gyu Lee, Hyun Chul Lee, Dae Hwan Kang
Abstract
DendGDP is sensitive to cathepsin B in tumor cells and can be used as a cathepsin B-responsive drug targeting strategy. We suggest that DendGDP is a promising vehicle for cancer cell targeting.
Related Papers
- → The dendritic effect illustrated with phosphorus dendrimers(2014)129 cited
- Dendrimers in medicine and biotechnology. New molecular tools(2006)
- → Force Biased Molecular Dynamics Simulation Study of Effect of Dendrimer Generation on Interaction with DNA(2012)25 cited
- → An alternative convergent synthesis of dendrimers with 2,5-diarylsilole at the core(2007)17 cited
- → Syntheses of Dendrimers and Dendrons(2011)6 cited